Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ITHACA

Financiado

Cerrado

Immuno targeting of human AML quiescent cells by a novel phage display approach.

One main objective of our ERC Advanced Grant project (InMec, No 341131) was to determine how cancer stem cells (CSCs) contribute to tumour growth, and the relative impact of quiescent versus proliferative CSCs. In Acute Myeloid L... ver más

30/06/2019

ISTITUTO EUROPEO D...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ISTITUTO EUROPEO DI ONCOLOGIA SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-06-30

ERC-2017-PoC: ERC-Proof of Concept

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

ISTITUTO EUROPEO DI ONCOLOGI...

150.00K€ | Lider

GILMA TECHNOLOGY

163.86K€ | Participante

TTF

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MOLTALL Molecularly targeted therapy for T cell acute lymphoblastic... 1M€ Cerrado

CMLMULTIHIT Establishment of a novel CML model using Multi Hit technolog... 171K€ Cerrado

PREDICT THE DRUG Using ex vivo functional genomics as biomarker to predict th... 150K€ Cerrado

PID2020-114638RA-I00 MECANISMOS MOLECULARES DE LA RESISTENCIA A TERAPIA Y PLASTIC... 229K€ Cerrado

PID2019-105404RB-I00 GENERATION DE NUEVAS HERRAMIENTAS IMMUNOTERAPEUTICAS PARA EL... 127K€ Cerrado

StemTarget Development of new therapeutic treatments targeting cancer s... 161K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2017-10-31
Fecha Fin: 2019-06-30

Líder del proyecto

ISTITUTO EUROPEO DI ONCOLOGIA SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto One main objective of our ERC Advanced Grant project (InMec, No 341131) was to determine how cancer stem cells (CSCs) contribute to tumour growth, and the relative impact of quiescent versus proliferative CSCs. In Acute Myeloid Leukaemia (AML), our results strongly suggest that quiescent leukaemia stem cells are critical for leukaemia maintenance and relapse after treatments. AML is an aggressive and frequently fatal hematologic malignancy. It is usually sensitive to chemotherapy at its onset, leading to disease remission in most patients; however, the majority of patient will later relapse and eventually die. Notably, leukaemia stem cells are often resistant to chemotherapy. We will use our innovative phage-display antibody screening platform to generate antibodies against AMLs. The screening will be performed directly on human AMLs growing in vivo, using an innovative mouse xenotransplantation model followed by an NGS-based antibody selection procedure. We plan to isolate antibodies that selectively recognize leukaemia stem cells, either quiescent or proliferating. Our primary goal is to develop novel therapeutic antibodies for the treatment of AMLs. This project will also indirectly confirm the hypothesis that leukaemia stem cells are the real fuel of the disease. We expect that this project will lead to quick and cheap identification, cloning and validation of human recombinant antibodies towards against AML leukemic stem cells. The use of phage display technology to isolate leukemic stem cell-specific human recombinant antibodies is to our knowledge unprecedented. The development of candidate antibodies against AMLs will be accompanied by the promotion of commercial/exploitation activities such as market and competition analyses, intellectual property management, and product and business development through the activities of our partner TTFactor.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores